ProfileGDS5678 / 1443463_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 61% 61% 57% 61% 64% 67% 60% 60% 60% 61% 61% 61% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.705561
GSM967853U87-EV human glioblastoma xenograft - Control 23.6326761
GSM967854U87-EV human glioblastoma xenograft - Control 33.6349961
GSM967855U87-EV human glioblastoma xenograft - Control 43.3835757
GSM967856U87-EV human glioblastoma xenograft - Control 53.5812761
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8981164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1281267
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5947860
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6008460
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5965360
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6269361
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6279361
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6381161
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6323661